Compromised T-cell immunity in turkeys may lead to an unpredictable avian metapneumovirus vaccine response and variable protection against challenge

Avian metapneumovirus (aMPV) is an important respiratory pathogen of turkeys with considerable economic impact on poultry production. Although vaccination is widely used for the control of the disease, questions regarding vaccine safety and efficacy remain to be elucidated. This report describes the problems associated with reproducibility of the aMPV-vaccine response, comparing T-lymphocyte-compromised and T-cell-intact turkeys. In three consecutive experiments, turkeys partially depleted of T-lymphocytes by treatment with cyclosporin A as well as untreated turkeys were vaccinated with a commercial live aMPV subtype A (aMPV-A) vaccine at 2 weeks of age. Two weeks later they were challenged with a virulent aMPV-A strain. Despite similar genetic background of the turkeys, comparable housing conditions under isolation and the application of the same aMPV-A vaccine, considerable variation was observed among the experiments regarding replication of the vaccine virus, vaccine-induced clinical signs and protection against challenge infection. The results indicate that differences in the outcome of aMPV-A vaccination may be associated with T-lymphocyte suppression and additionally with an interfering aMPV-B vaccine exposure at the hatchery in two of the experiments. Our study provides possible explanations for the variable protection provided by aMPV vaccines under field conditions.     

Interaction between a live avian pneumovirus vaccine and two different Newcastle disease virus vaccines in broiler chickens with maternal antibodies to Newcastle disease virus.

Broiler chicks with maternal antibodies to Newcastle disease virus (NDV) but none to avian metapneumovirus (APV) were divided into six groups. One group was kept as an unvaccinated control group. Three of the other groups were vaccinated at 1 day old with live APV vaccine or one of two live NDV vaccines (VG/GA or HB1). The remaining two groups received the APV vaccine in combination with either of the two NDV vaccines at 1 day old. At intervals after vaccination for up to 42 days, distribution of the viruses in the tissues was monitored, together with humoral antibody responses. Few NDV isolations were made from any NDV-vaccinated chicks, probably due to the presence of NDV maternal antibodies. In both dual-vaccinated groups, APV persisted longer (up to 21 days post vaccination (d.p.v.)) than in the single vaccinates (up to 14 d.p.v.). After 14 d.p.v., antibody titres against APV in both dual-vaccinated groups remained higher than the single APV vaccinates. For NDV haemagglutination inhibition antibodies, similar titres were found in the single and dual NDV VG/GA vaccinates. However, for chickens dually vaccinated with NDV HB1 and APV, the haemagglutination inhibition titres were significantly higher at 21 and 28 d.p.v. than the single HB1 vaccinates. These differences reflect the fact that NDV haemagglutination inhibition titres may depend on the NDV vaccine used.     

Study on the local effect of eye-drop vaccination against infectious bronchitis in 1-day-old chicks with maternal antibodies

One-day-old chicks with maternal antibodies to infectious bronchitis virus (IBV) were vaccinated by eye-drop with H120 vaccine strain of IBV. Four weeks later the chicks were challenged by eye-drop or intratracheally with virulent IBV (Massachusetts-type field strain). The chicks were resistant to ocular challenge, but highly susceptible to an intratracheal challenge. After intratracheal challenge the birds showed clinical signs of infectious bronchitis (IB). The immunofluorescence test on IBV was positive. Macroscopical and microscopical lesions were present in the trachea. From these observations it was concluded that the protection against virulent IBV after eye-drop vaccination is localised mainly in the conjunctival and nasal tissues. Thus in vaccination studies with IBV the result of challenge depended highly on the route of application of the challenge virus. Ten days after challenge the neutralisation index of serum for IBV was significantly higher in the intratracheally-challenged chicks as compared with their eye-drop challenged or/and unchallenged mates.     

Development and evaluation of an experimental vaccination program using a live avirulent Salmonella typhimurium strain to protect immunized chickens against challenge with homologous and heterologous Salmonella serotypes.

A stable live avirulent, genetically modified delta cya delta crp Salmonella typhimurium vaccine strain, chi 3985, was used in several vaccination strategies to evaluate its use in the control of Salmonella infection in chickens. Oral vaccination of chickens at 1 and at 14 days of age with 10(8) CFU of chi 3985 protected against invasion of spleen, ovary, and bursa of Fabricius and colonization of the ileum and cecum in chickens challenged with 10(6) CFU of virulent homologous Salmonella strains from group B. Chickens challenged with heterologous Salmonella strains from groups C, D, and E were protected against visceral invasion of spleen and ovary, while invasion of the bursa of Fabricius and colonization of ileum and cecum was reduced in vaccinated chickens. Oral vaccination at 2 and at 4 weeks of age induced an excellent protection against challenge with virulent group B Salmonella serotypes and very good protection against challenge with group D or E Salmonella serotypes, while protection against challenge with group C Salmonella serotypes was marginal but significant. Vaccination at 2 and at 4 weeks of age also protected vaccinated chickens against challenge with 10(8) CFU of highly invasive S. typhimurium or S. enteritidis strains. The protection of chickens vaccinated with chi 3985 against challenge with homologous and heterologous Salmonella serotypes is outstanding, and the complete protection against ovarian invasion in chickens challenged with 10(8) CFU of highly invasive S. typhimurium or S. enteritidis strains suggests that vaccination of chickens with chi 3985 can complement the present hygiene- and sanitation-based Salmonella control measures. This paper reports a breakthrough in the use of live avirulent vaccine to control Salmonella carriers in chickens.     

Day-old vaccination with live-in-oil vaccines: Newcastle disease (ND) and infectious bursal disease (IBD) in chicks and ND in turkey poults.

One-day-old broiler chicks were vaccinated with live Newcastle disease (ND) vaccine incorporated in oil alone or in killed-in-oil ND vaccine. Incorporation of live vaccine in oil emulsions was carried out just prior to vaccination. Live-in-oil ND vaccine containing 106.0 median embryo lethal doses (ELD50/dose induced the same protection following challenge and the same level of antibody at 42 days post-vaccination as did commercial killed-in-oil ND vaccine containing about 250 times as much antigen (108.4 ELD50/dose). Incorporation of live ND vaccine in killed-in-oil vaccine contributed markedly to protection rates and antibody levels, as compared to those obtained following vaccination with killed-in-oil vaccine only. One-day-old turkey poults also showed the advantage of incorporation of live ND vaccine in killed-in-oil vaccine when challenged 3 months post-vaccination. One-day-old broiler chicks, vaccinated with live ND and infectious bursal disease vaccine (IBD) incorporated in killed-in-oil combined ND + IBD vaccine, showed better protection against challenge with IBDV and higher antibody levels to NDV as compared to vaccination with killed-in-oil vaccine alone.     

Protection following simultaneous vaccination with three or four different attenuated live vaccine types against infectious bronchitis virus

ABSTRACT

Two or more different live attenuated infectious bronchitis virus (IBV) vaccine types are often given to broilers to induce homologous protection as well as to broaden protection against other IBV types in the field. However, the ability of broilers to respond to three or four different antigenic types of IBV vaccine has not been examined experimentally. In this study, we vaccinated one-day-old broiler chicks by eyedrop with three or four different IBV vaccine types simultaneously. The presence and relative amount of each vaccine was examined in all of the birds by IBV type-specific real-time RT–PCR at 5 days post-vaccination and each vaccine was detected in all of the birds given that vaccine. The birds were challenged at 28 days of age and protection was measured by clinical signs, virus detection and by ciliostasis. Birds vaccinated with three different IBV types (Ark, Mass and GA98) were protected against challenge with each of those IBV types and were partially protected against challenge with the GA08 virus. Birds vaccinated with four different IBV types (Ark, Mass, GA98 and GA08) were protected against challenge with each of those IBV types with the exception of Mass challenged birds which clearly had 3/11 birds not protected based on individual ciliostasis scores, but had an average ciliostasis score of >50% which is considered protected. The results are important for the control of IBV because they indicate that simultaneous vaccination with up to four different IBV vaccine types can provide adequate protection against challenge for each type.     

Assessment of vaccination of pigeons against paramyxovirus type 1 infection with inactivated aqueous-suspension or oil-emulsion vaccines

The immune response and resistance to PMV1 challenge of pigeons vaccinated with inactivated oil-emulsion (OE) or aqueous-suspension (AS) vaccines were compared. ASa was based on NDV LaSota strain, ASb on NDV Terumo strain, OEa on NDV Poletti strain and OEb on NDV Ulster 2C strain. Groups were each vaccinated subcutaneously with one of ASa (0.2ml), ASb (0.2ml), OEa (0.5ml), OEa (0.2ml) and OEb (0.5ml). An unvacci-nated group was kept as control. The immune response measured by HI tests was the highest with the single 0.2ml dose of ASa vaccine. The single 0.2ml dose of OEa vaccine produced a poor HI response. Challenge with 'pigeon' PMV1 (intramuscular + intranasal/ocular) one month after vaccination resulted in the vast majority of unvaccinated pigeons excreting virus in the laryngeal secretions and the faeces and all . birds died. In comparison, virus shedding and morbidity-mortality were significantly reduced in the five challenged vaccinated groups. However, morbidity-mortality was higher in the OE groups than in the AS groups. No ASa vaccinated pigeon developed clinical signs and only one ASb vaccinated pigeon presented nervous signs. In contrast, morbidity-mortality reached 30 and 35% in the OE vaccinated groups. Only the inactivated aqueous-suspension vaccines, especially that prepared from NDV LaSota strain, gave, after one dose injection (0.2ml), high resistance to a severe challenge with 'pigeon' PMV1.     

Experimental assessment of the pathogenicity of the Newcastle disease viruses from outbreaks in Great Britain in 1997 for chickens and turkeys,and the protection afforded by vaccination

The Newcastle disease virus isolated from healthy turkeys in outbreak GB 97/6 was used to challenge 4-week-old turkeys and chickens, which were either not vaccinated or had received a single dose of Hitchner B1 live vaccine 14 days earlier, by one of the intramuscular, intranasal or contact routes. Similar experiments were done in 38-day-old turkeys and chickens using virus isolated from severely sick chickens in outbreak GB 97/1. All vaccinated chickens showed low but measurable immune responses 14 days after vaccination, but only three of the turkeys had detectable antibodies. No vaccinated turkey or chicken showed any clinical sign after challenge with either virus. The virus from healthy turkeys in outbreak GB 97/6 induced clinical signs in 12/30 unvaccinated turkeys after challenge and 7/30 died. In unvaccinated chickens, challenge with this virus produced clinical signs in 25/30 birds and 21/30 died. In challenge experiments with the virus from outbreak GB 97/1 in chickens, 3/30 unvaccinated turkeys showed clinical signs and all three subsequently died. In contrast, 30/30 unvaccinated chickens challenged with this virus showed clinical signs and died. Vaccination did not prevent infection and excretion of either challenge virus. However, when compared with unvaccinated birds, vaccination reduced significantly the length of time virus was excreted and the overall proportion of swabs that were positive.     

Protective effect of vaccination in chicks with local infectious bronchitis viruses against field virus challenge.

Avian infectious bronchitis virus (IBV) causes tremendous economic losses to the poultry industry worldwide. Different serotypes of this virus show little cross-protection. The present study investigated the relationship between differences in the genotype based on the N-terminus of the spike protein and the protection provided by vaccination with IBVs. Cross-immunization tests were performed using both killed and live viruses in specific-pathogen-free chicks. One-day-old chicks were immunized with killed or high [10(5) 50% embryo infectious dose (EID50)] or low (10(3) EID50) doses of live IBV viruses and challenged with homologous or heterologous IBV strains. The immunization efficacy was evaluated by virus isolation from the challenged chicks. In the killed-virus and high-dose live-virus test groups, IBV vaccination protected against challenge by homologous but not heterologous IBV strains. However, a low dose of live IBV showed no protection against virulent IBV challenge. These results indicate that both the genotype based on the N-terminus of the spike protein and the virus dose are essential to IBV protection from immunization. Thus, development of vaccines from different local strains is necessary to control infectious bronchitis in poultry.     

Effect of phylogenetic diversity of velogenic Newcastle disease virus challenge on virus shedding post homologous and heterologous DNA vaccination in chickens

Newcastle disease (ND) is a highly devastating disease for the poultry industry as it causes high economic losses. In this present study, a DNA vaccine containing the F and HN surface antigens of a highly virulent Newcastle disease virus (NDV), NDV/1/Chicken/2005 (FJ939313), was successfully generated. Cell transfection test indicated that the vaccine expressed the F and HN genes in Hep-2 cells. The main objective of this study was to compare the extent of protection induced by DNA vaccination after homologous and heterologous NDV-challenge as determined by the amount of NDV shedding after challenge. NDV-antibody-negative chickens were vaccinated either once, twice or thrice intramuscularly at 7, 14 and 21 days old and were challenged 14 days post vaccination with either homologous virus (vaccine-matched velogenic viscerotropic Newcastle disease virus (vvNDV) strain, FJ939313), phylogenetically related to group VII, or a phylogenetically divergent heterologous virus (unmatched vvNDV strain, AY968809), which belongs to genogroup VI and shows 84.1% nucleotide similarity to the NDV-sequences of the DNA vaccine. Our data indicate that birds, which received a single dose of the DNA vaccine were poorly protected, and only 30–40% of these birds survived after challenge with high virus shedding titre. Multiple administration of the DNA vaccine induced high protection rates of 70–90% with reduced virus shedding compared to the non-vaccinated and challenged birds. Generally, homologous challenge led to reduced tracheal and cloacal shedding compared to the heterologous vvNDV strain. This study provides a promising approach for the control of ND in chickens using DNA vaccines, which are phylogenetically closely related to the circulating field strains.     

Vaccination of chickens against a Belgian nephropathogenic strain of infectious bronchitis virus B1648 using attenuated homologous and heterologous strains

White Leghorn chicks without and with maternally derived antibodies (MDA) to infectious bronchitis virus (IBV) and broiler chicks with MDA were vaccinated at 1 day of age either with H120 vaccine, combined H120 and D274 vaccines or with a non-commercial attenuated strain derived from the virulent Belgian nephropathogenic IBV strain, B1648. Protection following challenge with virulent B1648 was assessed 4 weeks later by virus isolation from the trachea, antigen detection in the kidney by immunofluorescence and mortality rates. Vaccination with either homologous or heterologous vaccines reduced the duration of virus replication in the trachea of all groups compared to unvaccinated controls. Homologous vaccination reduced the incidence of virus replication in the kidney. Heterologous vaccination (H120 to D274) did not reduce kidney infection in the MDA + groups; however, partial kidney-protection was found in the MDA - group. There was no correlation between serum antibody titres measured by ELISA and the degree of kidney protection.     

Oral immunization of pigs against classical swine fever. Course of the disease and virus transmission after simultaneous vaccination and infection

The efficacy of simultaneous vaccination of pigs against classical swine fever (CSF) and challenge was evaluated. In this study, domestic weanling pigs were vaccinated orally with a conventional live virus vaccine based on CSF virus (CSFV) C strain and were challenged simultaneously with CSFV of different virulence. All the animals vaccinated and challenged with a high dose of highly virulent Koslov strain died while three of five animals challenged with a low dose of highly virulent Alfort 187 strain survived, shed the virus in nasal secretions, developed antibodies, and four of them showed a transient viremia. All the animals vaccinated and challenged with the low virulent field isolate MV 140/Riems survived, showed a short viremia and developed antibodies. No CSFV or CSFV RNA could be detected in the animals surviving the infection. This study demonstrates that oral vaccination of wild boars in an infected area bears no risk for the development of a persistent CSF infection.     

Kinetics of serum and local haemagglutination inhibition antibodies in chicks following vaccination and experimental infection with Newcastle disease virus and their relation with immunity

Broiler chicks were vaccinated against Newcastle disease (ND) by nebulisation of live La Sota vaccine, or by intramuscular administration of inactivated oil emulsion vaccine. Local haemagglutination inhibition (HI) antibodies were detected in spray vaccinated chicks but not in those vaccinated intramuscularly. Initially local HI-titres in trachea, tears and saliva behaved in the same way as the serum HI-titre, but after maximum levels were reached approximately 10 days after vaccination, local HI-titres waned to levels that were no longer detectable after 4 weeks. Challenge exposure with velogenic Newcastle disease virus (NDV), showed that high post-vaccinal serum HI-titres were correlated with complete resistance to clinical disease but not to infection, as indicated by the prevention of virus multiplication in the trachea and also by the post-challenge serum HI-titres. Resistance to infection was only detected in spray vaccinated chicks. No relation was found between local HI-titres and resistance to experimental infection with velogenic NDV.     

A reovirus challenge model applicable in commercial broilers after live vaccination

The efficacy of live reovirus vaccines may be determined by challenge via the foot pad route 3 to 4 weeks after vaccination. Swelling and discoloration in the foot pad and shank are scored for a period of 14 days. The major disadvantages of this challenge model are the subjective judgement of gross foot pad and/or shank lesions, that it is very difficult to induce lesions in broilers, and that it causes animal suffering. Other reovirus challenge models are based on reisolation of the virus from different tissues or on scoring microscopic lesions in the tendons. Some disadvantages of these models are that they either cannot be used after vaccination with live reovirus because they cannot discriminate between vaccine and challenge virus or that the microscopic lesions scored need not necessarily be related to the challenge virus but may have been induced by other factors. Therefore, we have attempted to develop a reovirus challenge model that was an improvement on the existing ones, using isolation of reovirus from different organs followed by specific detection of the challenge virus with a monoclonal antibody that can discriminate between challenge and vaccine virus. The reovirus challenge model was examined in specific pathogen free (SPF) White Leghorn chickens and commercial broilers. In vivo studies were conducted to examine the efficacy of an attenuated reovirus vaccine in SPF White Leghorn chickens and commercial broilers with maternal immunity against reovirus. No challenge virus could be detected in any of the organs of the vaccinated chickens 3 and 10 days after challenge. In contrast, challenge virus could be isolated from the unvaccinated control group. At an increased challenge dose all unvaccinated challenge control birds were positive, while the vaccinated chickens were protected. It was shown that 1-day-old vaccination in the presence of maternal immunity was effective. It seemed that protection induced in broilers by the attenuated reovirus vaccine may not have been entirely humoral because in protected birds no antibodies against reovirus were detected by enzyme-linked immunosorbent at the time of challenge. Protection in these birds might therefore have been induced by cellular immunity.     

Efficacy of inactivated infectious bursal disease (IBD) vaccines: Comparison of serology with protection of progeny chickens against IBD virus strains of varying virulence

The efficacy of inactivated infectious bursal disease vaccines was determined by measuring both the antibody response of vaccinated chickens and clinical protection of progeny chicks from vaccinated dams. Similar virus neutralizing (VN) antibody titres were obtained in 4-week-old chickens and mature hens after vaccination with one vaccine dose. VN titres below 10 log 2 increased considerably between the fourth and seventh week after vaccination in 4-week-old chickens as well as in mature chickens. All 2-week-old progeny chicks with serum VN antibody titres of at least 9 log 2 were clinically protected against the classical virulent 52/70 infectious bursal disease virus (IBDV) strain, as well as against the very virulent IBDV (vvIBDV) strain D6948. However, vaccination often did not prevent subclinical infection in these 2-week-old progeny chicks, which often resulted in severe lymphocyte depletion in the bursa of Fabricius. Even a serum VN titre of 11 log 2 was not always sufficient to prevent severe bursal damage. Although 52/70 IBDV and vvIBDV were equally pathogenic in 2-weekold specific pathogen free chickens, significant higher maternal antibody titres were required to prevent the adverse effects of vvIBDV in comparison with 52/70 IBDV. The relation between the serological response of chickens after application of inactivated IBD vaccines and the protection of progeny chicks of vaccinated dams depended on both the virulence of the IBDV challenge strain and the IBDV strain in the vaccine.     

Interaction between live avian pneumovirus and Newcastle disease virus vaccines in specific pathogen free chickens.

One-day-old specific pathogen free White Leghorn chicks were vaccinated with live avian pneumovirus (APV) vaccine, live Newcastle disease virus (NDV) vaccine or both. At intervals up to 28 days after vaccination, distribution of the virus in the tissues was studied, together with humoral and mucosal antibody responses in lachrymal fluid and tracheal washes. APV vaccine was detected for almost twice as long in the dual vaccinates as in the single vaccinates. Higher numbers of isolations of ND virus vaccine were obtained from the dual rather than the single vaccinates at 7 days post-vaccination but the reverse occurred at 14 days. APV serum antibodies were significantly lower in the dual rather than the single vaccinates. However, there were similar levels of local APV-specific IgA in the lachrymal fluids of both single and dual APV vaccinates. NDV serum antibody titres in the dual vaccinates were significantly higher than in the singly NDV-vaccinated chickens. It appears that simultaneous vaccination of chicks with live APV and NDV vaccines causes temporary suppression of APV vaccine proliferation and reduces humoral antibody responses to it, although the antibody response to NDV is enhanced.     

Evaluation of vaccination against infectious laryngotracheitis (ILT) with recombinant herpesvirus of turkey (rHVT-LT) and chicken embryo origin (CEO) vaccines applied alone or in combination

ABSTRACT

The chicken embryo origin (CEO) infectious laryngotracheitis (ILT) live attenuated vaccines, although capable of protecting against disease and reducing challenge virus replication, can regain virulence. Recombinant ILT vaccines do not regain virulence but are partially successful at blocking challenge virus replication. The objective of this study was to evaluate the effect of rHVT-LT vaccination on CEO replication and how this vaccination strategy enhances protection and limits challenge virus transmission to naïve contact chickens. The rHVT-LT vaccine was administered at 1 day of age subcutaneously and the CEO vaccine was administered at 6 weeks of age via eye-drop or drinking water. CEO vaccine replication post vaccination, challenge virus replication and transmission post challenge were evaluated. After vaccination, only the group that received the CEO via eye-drop developed transient conjunctivitis. A significant decrease in CEO replication was detected for the rHVT-LT?+?CEO groups as compared to groups that received CEO alone. After challenge, reduction in clinical signs and challenge virus replication were observed in all vaccinated groups. However, among the vaccinated groups, the rHVT-LT group presented higher clinical signs and challenge virus replication. Transmission of the challenge virus to naïve contact chickens was only observed in the rHVT-LT vaccinated group of chickens. Overall, this study found that priming with rHVT-LT reduced CEO virus replication and the addition of a CEO vaccination provided a more robust protection than rHVT alone. Therefore, rHVT-LT?+?CEO vaccination strategy constitutes an alternative approach to gain better control of the disease.